Company Filing History:
Years Active: 2025
Title: John Cleveland: Innovator in Cancer Treatment
Introduction
John Cleveland is a prominent inventor based in Land O'Lakes, FL (US). He has made significant contributions to the field of cancer research, particularly in the treatment of STK11-loss cancers. His innovative approach focuses on enhancing the efficacy of immunotherapy for lung cancer patients.
Latest Patents
John Cleveland holds a patent for the treatment of STK11-loss cancers. The patent details a method that involves the inhibition of the ornithine decarboxylase 1-driven pathway to restore immunotherapeutic efficacy in lung cancer with lost STK11 function. Specifically, the patent discloses compositions and methods for treating lung cancer using an ornithine decarboxylase (ODC) inhibitor, such as difluoromethylornithine. This method can involve assaying the subject for STK11 function and treating the subject with immunotherapy, such as anti-PD-1/PD-L1 immunotherapy.
Career Highlights
John Cleveland is affiliated with the H. Lee Moffitt Cancer Center and Research Institute, Inc., where he conducts his research. His work has been instrumental in advancing the understanding and treatment of lung cancer, particularly in patients with specific genetic profiles.
Collaborations
Throughout his career, John has collaborated with notable colleagues, including Douglas W. Cress and Nicholas Gimbrone. These collaborations have further enriched his research and contributed to the development of innovative cancer treatments.
Conclusion
John Cleveland's work in cancer treatment exemplifies the impact of innovative research on patient care. His patent for treating STK11-loss cancers represents a significant advancement in the field, showcasing the potential of targeted therapies in improving immunotherapeutic outcomes.